Literature DB >> 20082480

Prevalence of diverticulosis in recurrent Clostridium difficile infection.

Michael J Lipp1, Odelya E Pagovich, David Rabin, Albert D Min, Brett B Bernstein.   

Abstract

AIM: To re-evaluate the theory that colonic diverticulosis is associated with relapse of Clostridium difficile associated disease (CDAD) in light of data suggesting increasing rates of CDAD infection and relapse.
METHODS: Charts were reviewed for patients with recurrent CDAD who had also had a prior colonoscopy or flexible sigmoidoscopy. An age and gender matched control group was used to compare the prevalence of diverticulosis.
RESULTS: Twenty-two patients met the study criteria, and the prevalence of diverticulosis in patients with CDAD relapse was 23% compared to 32% in age and sex matched controls (P = 0.44). A significant proportion of patients with CDAD relapse had co-morbidities associated with immune suppression.
CONCLUSION: Diverticulosis does not appear to be associated with CDAD relapse.

Entities:  

Mesh:

Year:  2010        PMID: 20082480      PMCID: PMC2807955          DOI: 10.3748/wjg.v16.i3.345

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  16 in total

1.  Reining in recurrent Clostridium difficile infection--who's at risk?

Authors:  Christina M Surawicz
Journal:  Gastroenterology       Date:  2009-02-25       Impact factor: 22.682

2.  Outbreak of Clostridium difficile-related diarrhoea in an adult oncology unit: risk factors and microbiological characteristics.

Authors:  E Blot; M-C Escande; D Besson; F Barbut; C Granpeix; B Asselain; M-C Falcou; P Pouillart
Journal:  J Hosp Infect       Date:  2003-03       Impact factor: 3.926

3.  Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea.

Authors:  Stavros Sougioultzis; Lorraine Kyne; Denise Drudy; Sarah Keates; Seema Maroo; Charalabos Pothoulakis; Paul J Giannasca; Cynthia K Lee; Michel Warny; Thomas P Monath; Ciarán P Kelly
Journal:  Gastroenterology       Date:  2005-03       Impact factor: 22.682

4.  Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters.

Authors:  Gregory J Babcock; Teresa J Broering; Hector J Hernandez; Robert B Mandell; Katherine Donahue; Naomi Boatright; Anne M Stack; Israel Lowy; Robert Graziano; Deborah Molrine; Donna M Ambrosino; William D Thomas
Journal:  Infect Immun       Date:  2006-09-11       Impact factor: 3.441

5.  Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea.

Authors:  L Kyne; M Warny; A Qamar; C P Kelly
Journal:  Lancet       Date:  2001-01-20       Impact factor: 79.321

6.  Bacterial diarrhea in persons with HIV infection, United States, 1992-2002.

Authors:  Travis H Sanchez; John T Brooks; Patrick S Sullivan; Marta Juhasz; Eric Mintz; Mark S Dworkin; Jeffrey L Jones
Journal:  Clin Infect Dis       Date:  2005-10-31       Impact factor: 9.079

7.  Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease.

Authors:  Lynne V McFarland; Gary W Elmer; Christina M Surawicz
Journal:  Am J Gastroenterol       Date:  2002-07       Impact factor: 10.864

8.  Recurrent Clostridium difficile disease: epidemiology and clinical characteristics.

Authors:  L V McFarland; C M Surawicz; M Rubin; R Fekety; G W Elmer; R N Greenberg
Journal:  Infect Control Hosp Epidemiol       Date:  1999-01       Impact factor: 3.254

9.  Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada.

Authors:  Jacques Pépin; Sophie Routhier; Sandra Gagnon; Isabel Brazeau
Journal:  Clin Infect Dis       Date:  2006-02-07       Impact factor: 9.079

10.  Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea.

Authors:  Stuart McPherson; Colin J Rees; Richard Ellis; Shelly Soo; Simon J Panter
Journal:  Dis Colon Rectum       Date:  2006-05       Impact factor: 4.585

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.